Loading
Type 1 Diabetes / Diabetes Mellitus, Type 1 / Heart Disease Risk Factors · Journal article
Annals of Medicine · March 13, 2026
A consensus or society position rather than new primary data.
This narrative review critically evaluates cardiovascular risk prediction in type 1 diabetes, concluding that generic risk calculators (SCORE2, ACC/AHA) demonstrate poor performance in T1D populations. T1D-specific equations such as Steno-Risk show superior discriminatory performance, yet still misclassify many patients with subclinical atherosclerosis as moderate risk, necessitating integration with imaging and biomarkers for precision stratification.
Journal article. Individuals with type 1 diabetes at risk for cardiovascular disease.
CVD reduces life expectancy by over a decade in T1D compared to the general population Generic risk calculators show poor diagnostic performance in T1D populations T1D-specific equations like Steno-Risk demonstrate superior discriminatory performance compared to generic scores
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should preferentially use T1D-specific risk equations (e.g., Steno-Risk, LIFE-T1D) over generic calculators for cardiovascular stratification. For patients classified as moderate risk, direct subclinical atherosclerosis screening (carotid ultrasound, CAC scoring) is recommended to guide individualized cardioprotective interventions.
Narrative review synthesizing evidence on T1D-specific cardiovascular risk equations versus generic tools, providing expert analysis to guide clinical stratification without presenting original data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should preferentially use T1D-specific risk equations (e.g., Steno-Risk, LIFE-T1D) over generic calculators for cardiovascular stratification. For patients classified as moderate risk, direct subclinical atherosclerosis screening (carotid ultrasound, CAC scoring) is recommended to guide individualized cardioprotective interventions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction. Cardiovascular disease (CVD) remains the leading cause of premature mortality in type 1 diabetes (T1D). Despite this burden, current prevention guidelines and risk stratification tools are largely extrapolated from type 2 diabetes or general populations, often failing to capture the unique pathophysiological drivers of atherosclerosis in T1D. This narrative review aims to critically evaluate current cardiovascular prevention strategies, identify the limitations of generic risk calculators, and analyse the clinical utility and discriminatory performance of population-specific risk equations.Discussion. Current clinical practice guidelines provide heterogeneous and inconsistent recommendations for T1D. Generic risk calculators (e.g. SCORE2, ACC/AHA pooled cohort equations) are limited by short-term prediction horizons and a lack of validation in T1D cohorts, frequently leading to poor diagnostic performances in this population. Conversely, T1D-specific equations, such as Steno Type 1 Risk Engine (Steno-Risk) and the emerging LIFE-T1D model, incorporate disease-specific variables such as diabetes duration or albuminuria. Available evidence indicates that T1D equations as Steno-Risk demonstrate superior discriminatory performance compared to generic scores identifying those individuals with higher cardiovascular risk. However, despite improved calibration, specific tools still classify a substantial proportion of patients with established subclinical atherosclerotic disease as 'moderate risk,' creating a grey area that complicates therapeutic decision-making.Conclusion. Generic cardiovascular risk algorithms are inadequate for the T1D population. While specific equations represent a significant advancement toward accurate stratification, mathematical models alone may be insufficient. Moving toward precision medicine requires a combined approach that integrates validated T1D-specific risk calculators with subclinical atherosclerosis screening (e.g. carotid ultrasound, CAC scoring) and novel biomarkers. This synergistic strategy is essential to refine classification in the 'moderate risk' category and guide individualised cardioprotective interventions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.